Albumin-Binding Protein Modules for Lower Dosing Frequency

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing biotherapeutics face challenges in extending their serum half-life due to factors such as cellular recycling mechanisms, necessitating improved methods to enhance their circulation time in the body.

Innovation Solution

Development of albumin binding proteins, specifically VHH domains with defined complementarity determining regions (CDRs), which are engineered to bind strongly to albumin, thereby prolonging the serum half-life of therapeutic molecules when fused with them.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Duration of action of moving object

If therapeutic molecules are administered conventionally, then they can treat diseases, but their serum half-life is short requiring frequent administration

Engineering Contradiction:

Improveserum half-lifeVSAvoidfrequency of administration

Core Design Contradiction:

Duration of action of moving objectVSProductivity

Solution Approach 1:

The patent introduces albumin as an intermediary carrier protein that binds to therapeutic molecules. This intermediary extends the circulation time of therapeutics by leveraging albumin's long half-life and its role in cellular recycling mechanisms, thereby reducing the frequency of administration required

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the pharmacokinetic parameters of therapeutic molecules by facilitating their binding to albumin. This parameter change specifically targets the serum half-life, transforming it from a short duration to an extended duration that aligns with albumin's circulation characteristics

Inventive Principle:

Principle #35Parameter changes

2Duration of action of moving object

If albumin binding proteins are developed to extend half-life, then serum half-life is prolonged, but the complexity of therapeutic molecule design increases

Engineering Contradiction:

Improveserum half-lifeVSAvoidtherapeutic molecule design

Core Design Contradiction:

Duration of action of moving objectVSDevice complexity

Solution Approach 1:

The patent segments the therapeutic system into two functional components: the original therapeutic molecule and the albumin binding protein (VHH domain). This segmentation allows the half-life extension function to be added as a separate module, simplifying the overall design approach while achieving the desired pharmacokinetic profile

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The albumin binding proteins significantly increase the half-life of therapeutic molecules, potentially by several folds, reducing the frequency of administration and enhancing therapeutic efficacy.

Implementation Method 1

albumin binding proteins... which are engineered to bind strongly to albumin, thereby prolonging the serum half-life of therapeutic molecules when fused with them

Methodology Applied

Scientific EffectProtein binding: Absorption (physical)

Data Source

PatentUS12459994B2Albumin binding proteins and methods of use

Publication Date: 2025.11.04 PARAGON THERAPEUTICS INC

AI summary

Provided herein are albumin binding proteins and methods of making and using thereof.